GE HealthCare Technologies Inc. (GEHC)
Pre-market:
| Previous close | 81.11 |
| Open | 81.50 |
| Bid | 74.97 x 200 |
| Ask | 83.28 x 600 |
| Day's range | 81.16 - 82.76 |
| 52-week range | 62.35 - 94.50 |
| Volume | |
| Avg. volume | 3,573,870 |
| Market cap | 37.763B |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | 24.05 |
| EPS (TTM) | 3.44 |
| Earnings date | N/A |
| Forward dividend & yield | 0.12 (0.15%) |
| Ex-dividend date | 18 Apr 2024 |
| 1y target est | 93.71 |
Simply Wall St.GE HealthCare Technologies (NASDAQ:GEHC) Has Some Way To Go To Become A Multi-Bagger
Did you know there are some financial metrics that can provide clues of a potential multi-bagger? Firstly, we'd want to...
- Business Wire
GE HealthCare to Hold an Investor Day in New York City on November 21, 2024
CHICAGO, May 06, 2024--GE HealthCare (Nasdaq: GEHC), a leader in precision care innovation, will host an investor day on Thursday, November 21, 2024, in New York, NY. GE HealthCare’s management team will present its growth strategies, technology portfolio, and vision for its businesses via a live webcast and will be accessible at https://investor.gehealthcare.com/news-events/events. More information, including registration details, will be available as the date draws closer.
Business WirePushing the Boundaries of Neuroscience with GE HealthCare’s SIGNA MAGNUS
CHICAGO, May 05, 2024--GE HealthCare (Nasdaq: GEHC) today unveiled SIGNA MAGNUS, an FDA 510(k) pending head-only magnetic resonance (MR) scanner designed to explore advancements in neuroscience, which have been restricted by the performance limitations of conventional whole-body MR systems. Neuroscience, particularly in the study of psychiatric diseases and neurological disorders such as Alzheimer’s, has been constrained by technological and biological limitations, leaving many aspects of the br
